Search for: "Wyeth Pharmaceuticals"
Results 581 - 600
of 976
Sort by Relevance
|
Sort by Date
29 Sep 2009, 11:19 am
Promethazine hydrochloride was formally manufactured by pharmaceutical giant Wyeth under the name Phenergan. [read post]
24 Sep 2009, 8:51 am
Wyeth argued that its labeling was sufficient because it had been approved by the FDA. [read post]
18 Sep 2009, 1:25 pm
Drug Industry Document Archive (DIDA) Adds Newly Released Wyeth Ghostwriting Documents In September 2009 (Posted by Tom Lamb at DrugInjuryWatch.com) A September 18, 2009 article, "Medical Editors Push for Crackdown on Ghostwriting", published by The New York Times (NYT) provides a very good overview of how some big pharmaceutical companies have effectively turned scientific articles into marketing vehicles for their new drugs by means of industry-financed… [read post]
18 Sep 2009, 2:40 am
Here are excerpts from the aticle: The drug, previously sold by Wyeth Pharmaceuticals Inc. under the brand name Phenergan, was at the heart of a U.S. [read post]
17 Sep 2009, 1:11 pm
The drug, previously sold by Wyeth Pharmaceuticals Inc. under the brand name Phenergan, was at the heart of a U.S. [read post]
17 Sep 2009, 7:08 am
Makers of injected promethazine, a sedative also used to treat nausea and vomiting, are being required to put the strongest warning possible on the product because it can cause tissue damage leading to amputation, the Food and Drug Administration said Wednesday.The drug, previously sold by Wyeth Pharmaceuticals Inc. under the brand name Phenergan, was at the heart of a U.S. [read post]
17 Sep 2009, 4:30 am
Given the size of the overdose, no alleged illegibility of the little lines on the cup could possibly have made the slightest difference in the result.What's going on in those cases is the same thing we've already commented about in the context of the big preemption cases, Wyeth v. [read post]
11 Sep 2009, 8:51 pm
"Here's the agenda: The endgame reinvented: preparing for an emerging pharmaceutical patent paradigm Patent reform and the pharmaceutical industry: anticipating and adapting to change Follow-on biologics: understanding the role of patents in health care reform and related consequences for life cycle strategies Wyeth v. [read post]
9 Sep 2009, 7:14 am
(America-Israel Patent Law) USPTO says some requests for patent term adjustment reconsideration are premature (Patent Docs) US: New York Times article ‘For Profit, Industry Seeks Cancer Drugs’ reports on cancer drug development (Patent Docs) Products Angiomax (Bivalirudin) – US: Last-minute extension of pharmaceutical product life, or just throwing up a smokescreen? [read post]
7 Sep 2009, 12:35 pm
The Court discussed several different subsidiaries in the U.S. and in Europe that use very similar variations on the name Wyeth Pharmaceutical, such as Wyeth Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Limited. [read post]
2 Sep 2009, 11:22 pm
Fujisawa Pharmaceutical Co., 464 F. [read post]
1 Sep 2009, 4:06 am
Fleeger, a Pennsylvania resident, sued defendants Wyeth (incorporated in Delaware and headquartered in New Jersey), its division Wyeth Pharmaceuticals (headquartered in Pennsylvania), and Greenstone, Ltd. [read post]
1 Sep 2009, 1:59 am
"
Howrey Can Use 'Ethical Wall' Over Client's Objections
"A Delaware federal judge has OKed Howrey's use of an "ethical wall" between the firm's U.S. lawyers opposing Wyeth in a U.S. patent case and its European attorneys working with the pharmaceutical company in an unrelated matter. [read post]
26 Aug 2009, 6:12 am
F. of L. files antitrust suit against Merck, alleging fraudulent procurement of a patent, improper listing of patent in Orange Book (Patent Docs) Singulair (Montelukast) – US: Merck get injunction preventing Teva from selling generic Montelukast: Merck Sharp & Dohme Pharmaceuticals SRL v Teva Pharmaceuticals USA (The IP Factor) (IP Watchdog) (SmartBrief) (SmartBrief) (GenericsWeb) [read post]
24 Aug 2009, 1:55 pm
Recently, we posted a story about Wyeth Pharmaceuticals “ghostwriting” medical journal articles. [read post]
20 Aug 2009, 3:40 am
Rather, the articles supported Wyeth’s position on the state of the science. [read post]
19 Aug 2009, 5:41 am
(Patent Docs) US: BIO files amicus brief in Bilski (Patent Docs) US: Jim Greenwood on data exclusivity and healthcare innovation (BiotechBlog) (IP Watchdog) (Patent Docs) US: European biosimilars market may hint at limited US threat (GenericsWeb) US: Chris Hansen on the Myriad lawsuit (Patents4Life) Products Effexor (Venlafaxine) – US: Wyeth files suit alleging Alphapharm’s Enlafax infringes its Venlafaxine patent; Generic Health, which recently… [read post]
17 Aug 2009, 4:17 pm
The Baltimore Injury Lawyer Blog has posted an article about protecting consumers from pharmaceutical negligence. [read post]
16 Aug 2009, 11:23 am
(Editor's Note: This post is based on a Simpson Thacher & Bartlett memorandum, which first appeared as an article in the New York Law Journal.) [read post]
12 Aug 2009, 4:21 pm
That supposed medical consensus benefited Wyeth, the pharmaceutical company that paid a medical communications firm to draft the papers, as sales of its hormone drugs, called Premarin and Prempro, soared to nearly $2 billion in 2001. [read post]
